Brief: Sedana Medical Submits Application For Market Approval For Sedaconda For Inhaled Sedation In Intensive Care In UK
Feb 19 (Reuters) - Sedana Medical AB (publ) SEDANA.ST :
* HAS SUBMITTED AN APPLICATION FOR MARKET APPROVAL FOR DRUG
CANDIDATE SEDACONDA (ISOFLURANE) FOR INHALED SEDATION IN
INTENSIVE CARE IN UK.
* SEDANA MEDICAL EXPECTS AN APPROVAL IN EU DURING SECOND
HALF OF
2021
Source text for Eikon: ID:nWkr8T7PyX
Further company coverage: SEDANA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Sedana Medical AB (publ)
See all newsSweden's Sedana Medical Q3 sales rise as growth returns
Brief: Sedana Medical Announces PDUFA Target Action Date
Brief: Sedana Medical Announces FDA Acceptance For Review Of Its New Drug Application In U.S.
Sweden's Sedana Medical Q2 sales flat, EBITDA loss narrows
Brief: Sedana Medical Q2 EBITDA Loss Narrows To SEK 1.9 Mln